Phase 1b Dose-finding Study of Venetoclax With Ibrutinib and Rituximab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma.

Petrillo, Alessandra; Ip, Andrew; Della Pia, Alexandra; Gill, Sarvainder; Zenreich, Joshua; Gutierrez, Martin; McNeill, Ann; Feldman, Tatyana; Leslie, Lori A; Goy, Andre

Petrillo, Alessandra; Ip, Andrew; Della Pia, Alexandra; Gill, Sarvainder; Zenreich, Joshua; Gutierrez, Martin; McNeill, Ann; Feldman, Tatyana; Leslie, Lori A; Goy, Andre.

Afiliação

Petrillo A; Hackensack University Medical Center, Hackensack, NJ, USA.
Ip A; Hackensack University Medical Center, Hackensack, NJ, USA.
Della Pia A; Hackensack Meridian School of Medicine, Nutley, NJ, USA.
Gill S; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Zenreich J; Hackensack University Medical Center, Hackensack, NJ, USA.
Gutierrez M; Ernest Mario School of Pharmacy at Rutgers University, Piscataway, NJ, USA.
McNeill A; Hackensack University Medical Center, Hackensack, NJ, USA.
Feldman T; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.
Leslie LA; Hackensack University Medical Center, Hackensack, NJ, USA.
Goy A; John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ, USA.

Hemasphere ; 6(6): e719, 2022 Jun.

Article em En | MEDLINE | ID: mdl-35747844

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Diagnostic_studies Idioma: En Revista: Hemasphere Ano de publicação: 2022 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google